Split (2)

train · 54.1k rows

uuid stringlengths 4 8	template_uuid stringclasses 40 values	question stringlengths 13 193	answer stringlengths 29 2.2k	benchmark_query stringlengths 133 622	execution_results stringlengths 2 1.14M	query_type stringclasses 2 values	sql_category stringclasses 26 values	bio_category stringclasses 14 values
Q16.697	Q16	What Small molecule therapies have been approved by the FDA to treat acute chest syndrome?	There are no drug Small molecule therapies approved to treat acute chest syndrome.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "acute chest syndrome" OR LOWER(mesh_heading) = "acute chest syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.178	Q16	What Protein therapies have been approved by the FDA to treat hypoparathyroidism?	There are no drug Protein therapies approved to treat hypoparathyroidism.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "hypoparathyroidism" OR LOWER(mesh_heading) = "hypoparathyroidism") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.853	Q16	What Small molecule therapies have been approved by the FDA to treat bronchopulmonary dysplasia?	There are no drug Small molecule therapies approved to treat bronchopulmonary dysplasia.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "bronchopulmonary dysplasia" OR LOWER(mesh_heading) = "bronchopulmonary dysplasia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.556	Q16	What Small molecule therapies have been approved by the FDA to treat Mydriasis?	Epinephrine is the only Small molecule therapy approved by the FDA to treat Mydriasis.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "mydriasis" OR LOWER(mesh_heading) = "mydriasis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_360821', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_360874', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_360927', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_360980', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_361033', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_361086', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_361139', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_361192', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_361245', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_361298', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_361351', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_361404', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_361457', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_361510', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_361563', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_361616', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_361669', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_361722', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_361775', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_361828', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_361881', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_361934', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_361987', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_362040', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_362093', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_362146', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_362199', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_362252', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_362305', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_362358', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_362411', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_362464', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_362517', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_362570', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_362623', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_362676', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_362729', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_362782', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_362835', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_362888', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_362941', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_362994', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_363047', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_363100', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_363153', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_363206', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_363259', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_363312', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_363365', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_363418', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_363471', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_363524', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_363577', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_363630', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_363683', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_363736', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_363789', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_363842', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_363895', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_363948', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_364001', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_364054', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_364107', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_364160', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_364213', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_364266', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_364319', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_364372', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_364425', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_364478', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_364531', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_364584', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_364637', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_364690', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_364743', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_364796', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_364849', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_364902', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_364955', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_365008', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_365061', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_365114', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_365167', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_365220', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_365273', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_365326', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_365379', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_365432', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_365485', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_365538', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_365591', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_365644', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_365697', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_365750', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_365803', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_365856', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_365909', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_365962', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_366015', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}, {'UUID': 'DrugTargetsIndication121923_text_366068', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.87	Q16	What Protein therapies have been approved by the FDA to treat age-related macular degeneration?	There are no drug Protein therapies approved to treat age-related macular degeneration.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "age-related macular degeneration" OR LOWER(mesh_heading) = "age-related macular degeneration") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1234	Q16	What Small molecule therapies have been approved by the FDA to treat kidney failure?	Metoclopramide Hydrochloride is the only Small molecule therapy approved by the FDA to treat kidney failure.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "kidney failure" OR LOWER(mesh_heading) = "kidney failure") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_199665', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency', 'efo_term': 'kidney failure'}, {'UUID': 'DrugTargetsIndication121923_text_199673', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency', 'efo_term': 'kidney failure'}, {'UUID': 'DrugTargetsIndication121923_text_199681', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency', 'efo_term': 'kidney failure'}, {'UUID': 'DrugTargetsIndication121923_text_199689', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency', 'efo_term': 'kidney failure'}, {'UUID': 'DrugTargetsIndication121923_text_199697', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000164270', 'approvedSymbol': 'HTR4', 'approvedName': '5-hydroxytryptamine receptor 4', 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency', 'efo_term': 'kidney failure'}, {'UUID': 'DrugTargetsIndication121923_text_199705', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000164270', 'approvedSymbol': 'HTR4', 'approvedName': '5-hydroxytryptamine receptor 4', 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency', 'efo_term': 'kidney failure'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1669	Q16	What Small molecule therapies have been approved by the FDA to treat sudden cardiac arrest?	There are no drug Small molecule therapies approved to treat sudden cardiac arrest.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "sudden cardiac arrest" OR LOWER(mesh_heading) = "sudden cardiac arrest") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_360826', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_360879', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_360932', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_360985', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361038', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361091', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361144', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361197', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361250', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361303', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361356', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361409', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361462', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361515', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361568', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361621', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361674', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361727', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361780', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361833', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361886', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361939', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361992', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362045', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362098', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362151', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362204', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362257', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362310', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362363', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362416', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362469', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362522', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362575', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362628', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362681', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362734', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362787', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362840', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362893', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362946', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362999', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363052', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363105', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363158', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363211', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363264', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363317', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363370', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363423', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363476', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363529', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363582', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363635', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363688', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363741', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363794', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363847', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363900', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363953', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364006', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364059', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364112', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364165', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364218', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364271', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364324', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364377', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364430', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364483', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364536', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364589', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364642', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364695', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364748', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364801', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364854', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364907', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364960', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365013', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365066', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365119', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365172', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365225', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365278', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365331', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365384', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365437', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365490', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365543', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365596', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365649', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365702', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365755', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365808', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365861', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365914', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365967', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_366020', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_366073', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.461	Q16	What Small molecule therapies have been approved by the FDA to treat Graves disease?	There are no drug Small molecule therapies approved to treat Graves disease.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "graves disease" OR LOWER(mesh_heading) = "graves disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.55	Q16	What Protein therapies have been approved by the FDA to treat Osteopenia?	There are no drug Protein therapies approved to treat Osteopenia.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "osteopenia" OR LOWER(mesh_heading) = "osteopenia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1321	Q16	What Small molecule therapies have been approved by the FDA to treat microscopic polyangiitis?	Avacopan is the only Small molecule therapy approved by the FDA to treat microscopic polyangiitis.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "microscopic polyangiitis" OR LOWER(mesh_heading) = "microscopic polyangiitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_1191850', 'drugName': 'Avacopan', 'tradeNames_list': "['Tavneos']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000197405', 'approvedSymbol': 'C5AR1', 'approvedName': 'complement C5a receptor 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Microscopic Polyangiitis', 'efo_term': 'microscopic polyangiitis'}, {'UUID': 'DrugTargetsIndication121923_text_1191858', 'drugName': 'Avacopan', 'tradeNames_list': "['Tavneos']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000197405', 'approvedSymbol': 'C5AR1', 'approvedName': 'complement C5a receptor 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Microscopic Polyangiitis', 'efo_term': 'microscopic polyangiitis'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.223	Q16	What Protein therapies have been approved by the FDA to treat mucopolysaccharidosis?	There are no drug Protein therapies approved to treat mucopolysaccharidosis.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "mucopolysaccharidosis" OR LOWER(mesh_heading) = "mucopolysaccharidosis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.114	Q16	What Protein therapies have been approved by the FDA to treat bulimia nervosa?	There are no drug Protein therapies approved to treat bulimia nervosa.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "bulimia nervosa" OR LOWER(mesh_heading) = "bulimia nervosa") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1741	Q16	What Small molecule therapies have been approved by the FDA to treat vaginal inflammation?	There are 2 Small molecule therapy drugs that are approved to treat vaginal inflammation which are as follows: Naproxen and Ibuprofen.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "vaginal inflammation" OR LOWER(mesh_heading) = "vaginal inflammation") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_838339', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_838380', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_838421', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_838462', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_838503', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_838544', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_838585', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_838626', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_838667', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_838708', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_838749', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_838790', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_838831', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_838872', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_838913', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_838954', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_838995', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_839036', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_839077', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_839118', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_839159', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_839200', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_839241', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_839282', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_839323', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_839364', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_839405', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_839446', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_839487', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_839528', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_839569', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_839610', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_839651', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_839692', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_839772', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_839851', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_839930', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_840009', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_840088', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_840167', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_840246', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_840325', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_840404', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_840483', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_840562', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_840641', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_840720', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_840799', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_840878', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_840957', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_841036', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_841115', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_841194', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_841273', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_841352', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_841431', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_841510', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_841589', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_841668', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_841747', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vaginitis', 'efo_term': 'vaginal inflammation'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1089	Q16	What Small molecule therapies have been approved by the FDA to treat gallbladder carcinoma?	There are no drug Small molecule therapies approved to treat gallbladder carcinoma.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "gallbladder carcinoma" OR LOWER(mesh_heading) = "gallbladder carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1758	Q16	What Small molecule therapies have been approved by the FDA to treat von Hippel-Lindau disease?	Belzutifan is the only Small molecule therapy approved by the FDA to treat von Hippel-Lindau disease.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "von hippel-lindau disease" OR LOWER(mesh_heading) = "von hippel-lindau disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_1192114', 'drugName': 'Belzutifan', 'tradeNames_list': "['Welireg']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116016', 'approvedSymbol': 'EPAS1', 'approvedName': 'endothelial PAS domain protein 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Hippel-Lindau Disease', 'efo_term': 'von Hippel-Lindau disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192122', 'drugName': 'Belzutifan', 'tradeNames_list': "['Welireg']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116016', 'approvedSymbol': 'EPAS1', 'approvedName': 'endothelial PAS domain protein 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Hippel-Lindau Disease', 'efo_term': 'von Hippel-Lindau disease'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.175	Q16	What Protein therapies have been approved by the FDA to treat hyperinsulinemic hypoglycemia?	There are no drug Protein therapies approved to treat hyperinsulinemic hypoglycemia.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "hyperinsulinemic hypoglycemia" OR LOWER(mesh_heading) = "hyperinsulinemic hypoglycemia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.618	Q16	What Small molecule therapies have been approved by the FDA to treat ST Elevation Myocardial Infarction?	There are no drug Small molecule therapies approved to treat ST Elevation Myocardial Infarction.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "st elevation myocardial infarction" OR LOWER(mesh_heading) = "st elevation myocardial infarction") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1374	Q16	What Small molecule therapies have been approved by the FDA to treat neuroepithelial neoplasm?	There are no drug Small molecule therapies approved to treat neuroepithelial neoplasm.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "neuroepithelial neoplasm" OR LOWER(mesh_heading) = "neuroepithelial neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.19	Q16	What Protein therapies have been approved by the FDA to treat Acute kidney injury?	There are no drug Protein therapies approved to treat Acute kidney injury.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "acute kidney injury" OR LOWER(mesh_heading) = "acute kidney injury") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.427	Q16	What Small molecule therapies have been approved by the FDA to treat Epiphora?	There are no drug Small molecule therapies approved to treat Epiphora.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "epiphora" OR LOWER(mesh_heading) = "epiphora") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1177	Q16	What Small molecule therapies have been approved by the FDA to treat hypotrichosis simplex?	Bimatoprost is the only Small molecule therapy approved by the FDA to treat hypotrichosis simplex.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "hypotrichosis simplex" OR LOWER(mesh_heading) = "hypotrichosis simplex") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_1149133', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149142', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149151', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149160', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149169', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149178', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149187', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149196', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149205', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149214', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149223', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149232', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149241', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149250', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149259', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149268', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149277', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149286', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149295', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149304', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149313', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149322', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149331', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149340', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149349', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149358', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149367', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149376', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149385', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149394', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149403', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.287	Q16	What Protein therapies have been approved by the FDA to treat sarcoma?	There are no drug Protein therapies approved to treat sarcoma.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "sarcoma" OR LOWER(mesh_heading) = "sarcoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1397	Q16	What Small molecule therapies have been approved by the FDA to treat oligoastrocytoma?	There are no drug Small molecule therapies approved to treat oligoastrocytoma.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "oligoastrocytoma" OR LOWER(mesh_heading) = "oligoastrocytoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.432	Q16	What Small molecule therapies have been approved by the FDA to treat Esophagitis?	There are 6 Small molecule therapy drugs that are approved to treat Esophagitis which are as follows: Pantoprazole Sodium, Esomeprazole Magnesium, Omeprazole, Dexlansoprazole, Nizatidine, and Famotidine.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "esophagitis" OR LOWER(mesh_heading) = "esophagitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_1097746', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097751', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097756', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097761', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097766', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097771', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097776', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097781', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097786', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097791', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097796', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097801', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097806', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097811', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097816', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097821', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097826', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097831', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097836', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097841', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097846', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097851', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097858', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097870', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097882', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097894', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1097965', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098035', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098105', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098175', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098245', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098315', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098422', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098430', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098438', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098446', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098454', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098462', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098470', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098478', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098486', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098494', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098502', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098510', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098518', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098526', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098534', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098542', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098550', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098558', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098566', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098574', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098582', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098590', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098598', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098606', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098614', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098622', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098630', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098638', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098646', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098654', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098662', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098670', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098678', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098686', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098694', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098702', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098710', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098718', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098726', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098734', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098742', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098750', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098758', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098766', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098774', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098782', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098790', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098798', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098806', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098814', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098822', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098830', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098838', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098846', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098854', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098862', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098870', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098878', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098886', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098894', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098902', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098910', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098918', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098926', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098934', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098942', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098950', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}, {'UUID': 'DrugTargetsIndication121923_text_1098958', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1329	Q16	What Small molecule therapies have been approved by the FDA to treat mononeuropathy?	There are no drug Small molecule therapies approved to treat mononeuropathy.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "mononeuropathy" OR LOWER(mesh_heading) = "mononeuropathy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.592	Q16	What Small molecule therapies have been approved by the FDA to treat Plantar Fasciitis?	There are no drug Small molecule therapies approved to treat Plantar Fasciitis.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "plantar fasciitis" OR LOWER(mesh_heading) = "plantar fasciitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.32	Q16	What Protein therapies have been approved by the FDA to treat Central precocious puberty?	There are 2 Protein therapy drugs that are approved to treat Central precocious puberty which are as follows: Leuprolide Acetate and Triptorelin Pamoate.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "central precocious puberty" OR LOWER(mesh_heading) = "central precocious puberty") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_1097005', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'Central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097008', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097027', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'Central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097030', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097049', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'Central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097052', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097071', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'Central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097074', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097093', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'Central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097096', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097115', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'Central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097118', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097287', 'drugName': 'Triptorelin Pamoate', 'tradeNames_list': "['Trelstar', 'Triptodur kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'Central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097294', 'drugName': 'Triptorelin Pamoate', 'tradeNames_list': "['Trelstar', 'Triptodur kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'Central precocious puberty'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1133	Q16	What Small molecule therapies have been approved by the FDA to treat hematopoietic and lymphoid cell neoplasm?	There are no drug Small molecule therapies approved to treat hematopoietic and lymphoid cell neoplasm.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "hematopoietic and lymphoid cell neoplasm" OR LOWER(mesh_heading) = "hematopoietic and lymphoid cell neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1623	Q16	What Small molecule therapies have been approved by the FDA to treat shoulder impingement syndrome?	There are no drug Small molecule therapies approved to treat shoulder impingement syndrome.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "shoulder impingement syndrome" OR LOWER(mesh_heading) = "shoulder impingement syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.216	Q16	What Protein therapies have been approved by the FDA to treat meningioma?	There are no drug Protein therapies approved to treat meningioma.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "meningioma" OR LOWER(mesh_heading) = "meningioma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1483	Q16	What Small molecule therapies have been approved by the FDA to treat placental insufficiency?	There are no drug Small molecule therapies approved to treat placental insufficiency.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "placental insufficiency" OR LOWER(mesh_heading) = "placental insufficiency") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.328	Q16	What Small molecule therapies have been approved by the FDA to treat Abnormality of connective tissue?	There are no drug Small molecule therapies approved to treat Abnormality of connective tissue.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "abnormality of connective tissue" OR LOWER(mesh_heading) = "abnormality of connective tissue") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.564	Q16	What Small molecule therapies have been approved by the FDA to treat Nausea and vomiting?	There are 8 Small molecule therapy drugs that are approved to treat Nausea and vomiting which are as follows: Amisulpride, Metoclopramide Hydrochloride, Palonosetron Hydrochloride, Granisetron, Ondansetron, Aprepitant, Fosaprepitant Dimeglumine, and Dronabinol.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "nausea and vomiting" OR LOWER(mesh_heading) = "nausea and vomiting") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_151446', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151459', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151472', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151485', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151498', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151511', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151524', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151537', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151550', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151563', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151576', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151589', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151602', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151615', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151628', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151641', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151654', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151667', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151680', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151693', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151706', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151719', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151732', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151745', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151758', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151771', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151784', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151797', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151810', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151823', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151836', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151849', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151862', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151875', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151888', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151901', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151914', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151927', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151940', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151953', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151966', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151979', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_151992', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152005', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152018', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152031', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152044', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152057', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151577', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152070', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152083', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152096', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152109', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152122', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152135', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152148', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152161', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152174', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152187', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152200', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152213', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152226', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152239', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152252', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152265', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152278', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152291', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152304', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152317', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152330', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152343', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152356', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152369', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152382', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152395', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152408', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152421', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152434', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152447', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152460', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152473', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152486', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152499', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152512', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152525', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152538', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152551', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152564', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152577', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152590', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152603', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152616', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152629', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152642', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152655', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152668', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152681', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000178394', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152694', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000186038', 'approvedSymbol': 'HTR3E', 'approvedName': '5-hydroxytryptamine receptor 3E', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152707', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000186038', 'approvedSymbol': 'HTR3E', 'approvedName': '5-hydroxytryptamine receptor 3E', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152720', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000186038', 'approvedSymbol': 'HTR3E', 'approvedName': '5-hydroxytryptamine receptor 3E', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_152733', 'drugName': 'Amisulpride', 'tradeNames_list': "['Barhemsys', 'Solian', 'Solian 100', 'Solian 200', 'Solian 400', 'Solian 50']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000186038', 'approvedSymbol': 'HTR3E', 'approvedName': '5-hydroxytryptamine receptor 3E', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1151	Q16	What Small molecule therapies have been approved by the FDA to treat hip fracture?	There are no drug Small molecule therapies approved to treat hip fracture.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "hip fracture" OR LOWER(mesh_heading) = "hip fracture") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1168	Q16	What Small molecule therapies have been approved by the FDA to treat hypogonadism?	There are 6 Small molecule therapy drugs that are approved to treat hypogonadism which are as follows: Bromocriptine Mesylate, Estradiol, Testosterone Cypionate, Testosterone Enanthate, Testosterone Undecanoate, and Testosterone.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "hypogonadism" OR LOWER(mesh_heading) = "hypogonadism") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_201342', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201349', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201356', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201363', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201370', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201377', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201384', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201391', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201398', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201405', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201412', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201419', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201426', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201433', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201440', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201447', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201454', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201461', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201468', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201475', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201482', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201489', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201496', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201503', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201510', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201517', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201524', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201531', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201538', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201545', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201552', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201559', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201566', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201573', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201580', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201587', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201594', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201601', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201608', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201615', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201622', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201629', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201636', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201643', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201650', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201657', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201664', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201671', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201678', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201685', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201692', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201699', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201706', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201713', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201720', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201727', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201734', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201741', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201748', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201755', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201762', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201769', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201776', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201783', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201790', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201797', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201804', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201811', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201818', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201825', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201832', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201839', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201846', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201853', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201860', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201867', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201874', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201881', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201888', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201895', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201902', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201909', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201916', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201923', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201930', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201937', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201944', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201951', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201958', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201965', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201972', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201979', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201986', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_201993', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_202000', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_202007', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_202014', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_202021', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_202028', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_202035', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1055	Q16	What Small molecule therapies have been approved by the FDA to treat facial pain?	There are no drug Small molecule therapies approved to treat facial pain.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "facial pain" OR LOWER(mesh_heading) = "facial pain") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.344	Q16	What Small molecule therapies have been approved by the FDA to treat Aplastic anemia?	There are 2 Small molecule therapy drugs that are approved to treat Aplastic anemia which are as follows: Prednisone and Dexamethasone.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "aplastic anemia" OR LOWER(mesh_heading) = "aplastic anemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_217624', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_217832', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_218040', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_218248', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_218456', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_218664', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_218872', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_219080', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_219288', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_219496', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_219704', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_219912', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_220120', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_220328', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_220536', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_220744', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_226315', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_226600', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_226885', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_227170', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_227455', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_227740', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_228025', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_228310', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_228595', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_228880', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_229165', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_229450', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_229735', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_230020', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_230305', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_230590', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_230875', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_231160', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_231445', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_231730', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_232015', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_232300', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.148	Q16	What Protein therapies have been approved by the FDA to treat digestive system neuroendocrine neoplasm?	There are no drug Protein therapies approved to treat digestive system neuroendocrine neoplasm.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "digestive system neuroendocrine neoplasm" OR LOWER(mesh_heading) = "digestive system neuroendocrine neoplasm") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.363	Q16	What Small molecule therapies have been approved by the FDA to treat Bilateral tonic-clonic seizure?	There are 2 Small molecule therapy drugs that are approved to treat Bilateral tonic-clonic seizure which are as follows: Lamotrigine and Levetiracetam.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "bilateral tonic-clonic seizure" OR LOWER(mesh_heading) = "bilateral tonic-clonic seizure") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_652994', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653025', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653056', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653087', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653118', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653149', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653180', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653211', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653242', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653273', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653304', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653335', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653366', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653397', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653428', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653459', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653490', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653521', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653552', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653583', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653614', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653645', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653676', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653707', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653738', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653769', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653800', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653831', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653862', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653893', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653924', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653955', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_653986', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654017', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654048', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654079', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654110', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654141', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654172', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654203', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654234', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654265', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654296', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654327', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654358', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654389', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654420', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654451', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654482', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654513', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654544', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654575', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654606', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654637', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654668', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654699', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654730', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654761', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654792', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654823', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654854', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654885', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654916', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654947', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_654978', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655009', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655040', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655071', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655102', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655133', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655164', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655195', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655226', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655257', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655288', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655319', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655350', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655381', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655412', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655443', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655474', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655505', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655536', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655567', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655598', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655629', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655660', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655691', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655722', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655753', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655784', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655815', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655846', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655877', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655908', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655939', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_655970', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_656001', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_656032', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}, {'UUID': 'DrugTargetsIndication121923_text_656063', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.84	Q16	What Protein therapies have been approved by the FDA to treat acute myocardial infarction?	There are no drug Protein therapies approved to treat acute myocardial infarction.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "acute myocardial infarction" OR LOWER(mesh_heading) = "acute myocardial infarction") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.49	Q16	What Protein therapies have been approved by the FDA to treat Leber hereditary optic neuropathy?	There are no drug Protein therapies approved to treat Leber hereditary optic neuropathy.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "leber hereditary optic neuropathy" OR LOWER(mesh_heading) = "leber hereditary optic neuropathy") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.472	Q16	What Small molecule therapies have been approved by the FDA to treat Hallux valgus?	There are no drug Small molecule therapies approved to treat Hallux valgus.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "hallux valgus" OR LOWER(mesh_heading) = "hallux valgus") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.156	Q16	What Protein therapies have been approved by the FDA to treat erythropoietic protoporphyria?	Afamelanotide is the only Protein therapy approved by the FDA to treat erythropoietic protoporphyria.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "erythropoietic protoporphyria" OR LOWER(mesh_heading) = "erythropoietic protoporphyria") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_1097737', 'drugName': 'Afamelanotide', 'tradeNames_list': "['Scenesse']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000258839', 'approvedSymbol': 'MC1R', 'approvedName': 'melanocortin 1 receptor', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Protoporphyria, Erythropoietic', 'efo_term': 'erythropoietic protoporphyria'}, {'UUID': 'DrugTargetsIndication121923_text_1097743', 'drugName': 'Afamelanotide', 'tradeNames_list': "['Scenesse']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000258839', 'approvedSymbol': 'MC1R', 'approvedName': 'melanocortin 1 receptor', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Protoporphyria, Erythropoietic', 'efo_term': 'erythropoietic protoporphyria'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1429	Q16	What Small molecule therapies have been approved by the FDA to treat ovarian carcinoma?	There are 5 Small molecule therapy drugs that are approved to treat ovarian carcinoma which are as follows: Gemcitabine Hydrochloride, Rucaparib Camsylate, Olaparib, Niraparib Tosylate, and Topotecan Hydrochloride.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "ovarian carcinoma" OR LOWER(mesh_heading) = "ovarian carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_755799', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101868', 'approvedSymbol': 'POLA1', 'approvedName': 'DNA polymerase alpha 1, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_755853', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101868', 'approvedSymbol': 'POLA1', 'approvedName': 'DNA polymerase alpha 1, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_755907', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101868', 'approvedSymbol': 'POLA1', 'approvedName': 'DNA polymerase alpha 1, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_755961', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101868', 'approvedSymbol': 'POLA1', 'approvedName': 'DNA polymerase alpha 1, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_756015', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101868', 'approvedSymbol': 'POLA1', 'approvedName': 'DNA polymerase alpha 1, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_756069', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101868', 'approvedSymbol': 'POLA1', 'approvedName': 'DNA polymerase alpha 1, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_756123', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101868', 'approvedSymbol': 'POLA1', 'approvedName': 'DNA polymerase alpha 1, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_756177', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101868', 'approvedSymbol': 'POLA1', 'approvedName': 'DNA polymerase alpha 1, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_756231', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101868', 'approvedSymbol': 'POLA1', 'approvedName': 'DNA polymerase alpha 1, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_756285', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101868', 'approvedSymbol': 'POLA1', 'approvedName': 'DNA polymerase alpha 1, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_756339', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000175482', 'approvedSymbol': 'POLD4', 'approvedName': 'DNA polymerase delta 4, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_756393', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000175482', 'approvedSymbol': 'POLD4', 'approvedName': 'DNA polymerase delta 4, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_756447', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000175482', 'approvedSymbol': 'POLD4', 'approvedName': 'DNA polymerase delta 4, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_756501', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000175482', 'approvedSymbol': 'POLD4', 'approvedName': 'DNA polymerase delta 4, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_756555', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000175482', 'approvedSymbol': 'POLD4', 'approvedName': 'DNA polymerase delta 4, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_756609', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000175482', 'approvedSymbol': 'POLD4', 'approvedName': 'DNA polymerase delta 4, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_756663', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000175482', 'approvedSymbol': 'POLD4', 'approvedName': 'DNA polymerase delta 4, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_756717', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000175482', 'approvedSymbol': 'POLD4', 'approvedName': 'DNA polymerase delta 4, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_756771', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000175482', 'approvedSymbol': 'POLD4', 'approvedName': 'DNA polymerase delta 4, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_756825', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000175482', 'approvedSymbol': 'POLD4', 'approvedName': 'DNA polymerase delta 4, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_756879', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077514', 'approvedSymbol': 'POLD3', 'approvedName': 'DNA polymerase delta 3, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_756933', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077514', 'approvedSymbol': 'POLD3', 'approvedName': 'DNA polymerase delta 3, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_756987', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077514', 'approvedSymbol': 'POLD3', 'approvedName': 'DNA polymerase delta 3, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_757041', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077514', 'approvedSymbol': 'POLD3', 'approvedName': 'DNA polymerase delta 3, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_757095', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077514', 'approvedSymbol': 'POLD3', 'approvedName': 'DNA polymerase delta 3, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_757149', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077514', 'approvedSymbol': 'POLD3', 'approvedName': 'DNA polymerase delta 3, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_757203', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077514', 'approvedSymbol': 'POLD3', 'approvedName': 'DNA polymerase delta 3, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_757257', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077514', 'approvedSymbol': 'POLD3', 'approvedName': 'DNA polymerase delta 3, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_757311', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077514', 'approvedSymbol': 'POLD3', 'approvedName': 'DNA polymerase delta 3, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_757365', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077514', 'approvedSymbol': 'POLD3', 'approvedName': 'DNA polymerase delta 3, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_757419', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000062822', 'approvedSymbol': 'POLD1', 'approvedName': 'DNA polymerase delta 1, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_757473', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000062822', 'approvedSymbol': 'POLD1', 'approvedName': 'DNA polymerase delta 1, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_757527', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000062822', 'approvedSymbol': 'POLD1', 'approvedName': 'DNA polymerase delta 1, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_757581', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000062822', 'approvedSymbol': 'POLD1', 'approvedName': 'DNA polymerase delta 1, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_757635', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000062822', 'approvedSymbol': 'POLD1', 'approvedName': 'DNA polymerase delta 1, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_757689', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000062822', 'approvedSymbol': 'POLD1', 'approvedName': 'DNA polymerase delta 1, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_757743', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000062822', 'approvedSymbol': 'POLD1', 'approvedName': 'DNA polymerase delta 1, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_757797', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000062822', 'approvedSymbol': 'POLD1', 'approvedName': 'DNA polymerase delta 1, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_757851', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000062822', 'approvedSymbol': 'POLD1', 'approvedName': 'DNA polymerase delta 1, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_757905', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000062822', 'approvedSymbol': 'POLD1', 'approvedName': 'DNA polymerase delta 1, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_757959', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106628', 'approvedSymbol': 'POLD2', 'approvedName': 'DNA polymerase delta 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_758013', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106628', 'approvedSymbol': 'POLD2', 'approvedName': 'DNA polymerase delta 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_758067', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106628', 'approvedSymbol': 'POLD2', 'approvedName': 'DNA polymerase delta 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_758121', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106628', 'approvedSymbol': 'POLD2', 'approvedName': 'DNA polymerase delta 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_758175', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106628', 'approvedSymbol': 'POLD2', 'approvedName': 'DNA polymerase delta 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_758229', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106628', 'approvedSymbol': 'POLD2', 'approvedName': 'DNA polymerase delta 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_758283', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106628', 'approvedSymbol': 'POLD2', 'approvedName': 'DNA polymerase delta 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_758337', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106628', 'approvedSymbol': 'POLD2', 'approvedName': 'DNA polymerase delta 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_758391', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106628', 'approvedSymbol': 'POLD2', 'approvedName': 'DNA polymerase delta 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_758445', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106628', 'approvedSymbol': 'POLD2', 'approvedName': 'DNA polymerase delta 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_758499', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000177084', 'approvedSymbol': 'POLE', 'approvedName': 'DNA polymerase epsilon, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_758553', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000177084', 'approvedSymbol': 'POLE', 'approvedName': 'DNA polymerase epsilon, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_758607', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000177084', 'approvedSymbol': 'POLE', 'approvedName': 'DNA polymerase epsilon, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_758661', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000177084', 'approvedSymbol': 'POLE', 'approvedName': 'DNA polymerase epsilon, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_758715', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000177084', 'approvedSymbol': 'POLE', 'approvedName': 'DNA polymerase epsilon, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_758769', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000177084', 'approvedSymbol': 'POLE', 'approvedName': 'DNA polymerase epsilon, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_758823', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000177084', 'approvedSymbol': 'POLE', 'approvedName': 'DNA polymerase epsilon, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_758877', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000177084', 'approvedSymbol': 'POLE', 'approvedName': 'DNA polymerase epsilon, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_758931', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000177084', 'approvedSymbol': 'POLE', 'approvedName': 'DNA polymerase epsilon, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_758985', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000177084', 'approvedSymbol': 'POLE', 'approvedName': 'DNA polymerase epsilon, catalytic subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_759039', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000014138', 'approvedSymbol': 'POLA2', 'approvedName': 'DNA polymerase alpha 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_759093', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000014138', 'approvedSymbol': 'POLA2', 'approvedName': 'DNA polymerase alpha 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_759147', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000014138', 'approvedSymbol': 'POLA2', 'approvedName': 'DNA polymerase alpha 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_759201', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000014138', 'approvedSymbol': 'POLA2', 'approvedName': 'DNA polymerase alpha 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_759255', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000014138', 'approvedSymbol': 'POLA2', 'approvedName': 'DNA polymerase alpha 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_759309', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000014138', 'approvedSymbol': 'POLA2', 'approvedName': 'DNA polymerase alpha 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_759363', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000014138', 'approvedSymbol': 'POLA2', 'approvedName': 'DNA polymerase alpha 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_759417', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000014138', 'approvedSymbol': 'POLA2', 'approvedName': 'DNA polymerase alpha 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_759471', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000014138', 'approvedSymbol': 'POLA2', 'approvedName': 'DNA polymerase alpha 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_759525', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000014138', 'approvedSymbol': 'POLA2', 'approvedName': 'DNA polymerase alpha 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_759579', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198056', 'approvedSymbol': 'PRIM1', 'approvedName': 'DNA primase subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_759633', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198056', 'approvedSymbol': 'PRIM1', 'approvedName': 'DNA primase subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_759687', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198056', 'approvedSymbol': 'PRIM1', 'approvedName': 'DNA primase subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_759741', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198056', 'approvedSymbol': 'PRIM1', 'approvedName': 'DNA primase subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_759795', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198056', 'approvedSymbol': 'PRIM1', 'approvedName': 'DNA primase subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_759849', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198056', 'approvedSymbol': 'PRIM1', 'approvedName': 'DNA primase subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_759903', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198056', 'approvedSymbol': 'PRIM1', 'approvedName': 'DNA primase subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_759957', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198056', 'approvedSymbol': 'PRIM1', 'approvedName': 'DNA primase subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_760011', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198056', 'approvedSymbol': 'PRIM1', 'approvedName': 'DNA primase subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_760065', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198056', 'approvedSymbol': 'PRIM1', 'approvedName': 'DNA primase subunit 1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_760119', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146143', 'approvedSymbol': 'PRIM2', 'approvedName': 'DNA primase subunit 2', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_760173', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146143', 'approvedSymbol': 'PRIM2', 'approvedName': 'DNA primase subunit 2', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_760227', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146143', 'approvedSymbol': 'PRIM2', 'approvedName': 'DNA primase subunit 2', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_760281', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146143', 'approvedSymbol': 'PRIM2', 'approvedName': 'DNA primase subunit 2', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_760335', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146143', 'approvedSymbol': 'PRIM2', 'approvedName': 'DNA primase subunit 2', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_760389', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146143', 'approvedSymbol': 'PRIM2', 'approvedName': 'DNA primase subunit 2', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_760443', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146143', 'approvedSymbol': 'PRIM2', 'approvedName': 'DNA primase subunit 2', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_760497', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146143', 'approvedSymbol': 'PRIM2', 'approvedName': 'DNA primase subunit 2', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_760551', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146143', 'approvedSymbol': 'PRIM2', 'approvedName': 'DNA primase subunit 2', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_760605', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146143', 'approvedSymbol': 'PRIM2', 'approvedName': 'DNA primase subunit 2', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_760659', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100479', 'approvedSymbol': 'POLE2', 'approvedName': 'DNA polymerase epsilon 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_760713', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100479', 'approvedSymbol': 'POLE2', 'approvedName': 'DNA polymerase epsilon 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_760767', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100479', 'approvedSymbol': 'POLE2', 'approvedName': 'DNA polymerase epsilon 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_760821', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100479', 'approvedSymbol': 'POLE2', 'approvedName': 'DNA polymerase epsilon 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_760875', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100479', 'approvedSymbol': 'POLE2', 'approvedName': 'DNA polymerase epsilon 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_760929', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100479', 'approvedSymbol': 'POLE2', 'approvedName': 'DNA polymerase epsilon 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_760983', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100479', 'approvedSymbol': 'POLE2', 'approvedName': 'DNA polymerase epsilon 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_761037', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100479', 'approvedSymbol': 'POLE2', 'approvedName': 'DNA polymerase epsilon 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_761091', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100479', 'approvedSymbol': 'POLE2', 'approvedName': 'DNA polymerase epsilon 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_761145', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_list': "['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100479', 'approvedSymbol': 'POLE2', 'approvedName': 'DNA polymerase epsilon 2, accessory subunit', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1229	Q16	What Small molecule therapies have been approved by the FDA to treat keratitis?	There are 2 Small molecule therapy drugs that are approved to treat keratitis which are as follows: Prednisone and Dexamethasone.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "keratitis" OR LOWER(mesh_heading) = "keratitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_217659', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_217867', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_218075', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_218283', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_218491', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_218699', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_218907', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_219115', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_219323', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_219531', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_219739', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_219947', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_220155', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_220363', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_220571', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_220779', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_226354', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_226639', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_226924', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_227209', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_227494', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_227779', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_228064', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_228349', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_228634', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_228919', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_229204', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_229489', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_229774', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_230059', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_230344', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_230629', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_230914', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_231199', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_231484', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_231769', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_232054', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}, {'UUID': 'DrugTargetsIndication121923_text_232339', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1067	Q16	What Small molecule therapies have been approved by the FDA to treat femoral neck fracture?	There are no drug Small molecule therapies approved to treat femoral neck fracture.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "femoral neck fracture" OR LOWER(mesh_heading) = "femoral neck fracture") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1523	Q16	What Small molecule therapies have been approved by the FDA to treat primary brain neoplasm?	There are no drug Small molecule therapies approved to treat primary brain neoplasm.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "primary brain neoplasm" OR LOWER(mesh_heading) = "primary brain neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.504	Q16	What Small molecule therapies have been approved by the FDA to treat Hypertriglyceridemia?	There are no drug Small molecule therapies approved to treat Hypertriglyceridemia.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "hypertriglyceridemia" OR LOWER(mesh_heading) = "hypertriglyceridemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.180	Q16	What Protein therapies have been approved by the FDA to treat immune system disease?	There are 3 Protein therapy drugs that are approved to treat immune system disease which are as follows: Cyclosporine, Pegcetacoplan, and Voclosporin.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "immune system disease" OR LOWER(mesh_heading) = "immune system disease") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_1100645', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1100772', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1100899', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1101026', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1101153', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1101280', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1101407', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1101534', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1101661', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1101788', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1101915', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1102042', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1102169', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1102296', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1102423', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1102550', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1102677', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1102804', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1102931', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1103058', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1103117', 'drugName': 'Pegcetacoplan', 'tradeNames_list': "['Empaveli']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000125730', 'approvedSymbol': 'C3', 'approvedName': 'complement C3', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1103123', 'drugName': 'Pegcetacoplan', 'tradeNames_list': "['Empaveli']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000125730', 'approvedSymbol': 'C3', 'approvedName': 'complement C3', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1103129', 'drugName': 'Pegcetacoplan', 'tradeNames_list': "['Empaveli']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000125730', 'approvedSymbol': 'C3', 'approvedName': 'complement C3', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1103135', 'drugName': 'Pegcetacoplan', 'tradeNames_list': "['Empaveli']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000125730', 'approvedSymbol': 'C3', 'approvedName': 'complement C3', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1103141', 'drugName': 'Pegcetacoplan', 'tradeNames_list': "['Empaveli']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000125730', 'approvedSymbol': 'C3', 'approvedName': 'complement C3', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1103147', 'drugName': 'Pegcetacoplan', 'tradeNames_list': "['Empaveli']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000125730', 'approvedSymbol': 'C3', 'approvedName': 'complement C3', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1103153', 'drugName': 'Pegcetacoplan', 'tradeNames_list': "['Empaveli']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000125730', 'approvedSymbol': 'C3', 'approvedName': 'complement C3', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1103159', 'drugName': 'Pegcetacoplan', 'tradeNames_list': "['Empaveli']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000125730', 'approvedSymbol': 'C3', 'approvedName': 'complement C3', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1103165', 'drugName': 'Pegcetacoplan', 'tradeNames_list': "['Empaveli']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000125730', 'approvedSymbol': 'C3', 'approvedName': 'complement C3', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1103171', 'drugName': 'Pegcetacoplan', 'tradeNames_list': "['Empaveli']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000125730', 'approvedSymbol': 'C3', 'approvedName': 'complement C3', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1103177', 'drugName': 'Pegcetacoplan', 'tradeNames_list': "['Empaveli']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000125730', 'approvedSymbol': 'C3', 'approvedName': 'complement C3', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192226', 'drugName': 'Voclosporin', 'tradeNames_list': "['Lupkynis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000138814', 'approvedSymbol': 'PPP3CA', 'approvedName': 'protein phosphatase 3 catalytic subunit alpha', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192238', 'drugName': 'Voclosporin', 'tradeNames_list': "['Lupkynis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000138814', 'approvedSymbol': 'PPP3CA', 'approvedName': 'protein phosphatase 3 catalytic subunit alpha', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.854	Q16	What Small molecule therapies have been approved by the FDA to treat brucellosis?	Doxycycline is the only Small molecule therapy approved by the FDA to treat brucellosis.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "brucellosis" OR LOWER(mesh_heading) = "brucellosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_1037848', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1037923', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1037998', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1038073', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1038148', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1038223', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1038298', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1038373', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1038448', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1038523', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1038598', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1038673', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1038748', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1038823', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1038898', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1038973', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1039048', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1039123', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1039198', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1039273', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1039348', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1039423', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1039498', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1039573', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1039648', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1039723', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1039798', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1039873', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1039948', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1040023', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1040098', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1040173', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1040248', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1040323', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1040398', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1040473', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1040548', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1040623', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1040698', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1040773', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1040848', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1040923', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1040998', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}, {'UUID': 'DrugTargetsIndication121923_text_1041073', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brucellosis', 'efo_term': 'brucellosis'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.621	Q16	What Small molecule therapies have been approved by the FDA to treat Sezary's disease?	There are no drug Small molecule therapies approved to treat Sezary's disease.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "sezary's disease" OR LOWER(mesh_heading) = "sezary's disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1213	Q16	What Small molecule therapies have been approved by the FDA to treat intracranial hemorrhage?	There are no drug Small molecule therapies approved to treat intracranial hemorrhage.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "intracranial hemorrhage" OR LOWER(mesh_heading) = "intracranial hemorrhage") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.532	Q16	What Small molecule therapies have been approved by the FDA to treat Leber congenital amaurosis?	There are no drug Small molecule therapies approved to treat Leber congenital amaurosis.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "leber congenital amaurosis" OR LOWER(mesh_heading) = "leber congenital amaurosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.349	Q16	What Small molecule therapies have been approved by the FDA to treat Asperger syndrome?	There are no drug Small molecule therapies approved to treat Asperger syndrome.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "asperger syndrome" OR LOWER(mesh_heading) = "asperger syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1514	Q16	What Small molecule therapies have been approved by the FDA to treat prediabetes syndrome?	There are no drug Small molecule therapies approved to treat prediabetes syndrome.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "prediabetes syndrome" OR LOWER(mesh_heading) = "prediabetes syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1724	Q16	What Small molecule therapies have been approved by the FDA to treat uremia?	There are no drug Small molecule therapies approved to treat uremia.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "uremia" OR LOWER(mesh_heading) = "uremia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.896	Q16	What Small molecule therapies have been approved by the FDA to treat childhood cancer?	There are 2 Small molecule therapy drugs that are approved to treat childhood cancer which are as follows: Dasatinib and Plerixafor.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "childhood cancer" OR LOWER(mesh_heading) = "childhood cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_713210', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_713288', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_713366', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_713444', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_713522', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_713600', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_713678', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_713756', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_713834', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_713912', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_713990', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_714068', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_714146', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_714224', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_714302', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_714380', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_714458', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_714536', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_714614', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_714692', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_714770', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_714848', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_714926', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_715004', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_715082', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_715160', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_715238', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_715316', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_715394', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_715472', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_715550', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_715628', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_715706', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_715784', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_715862', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_715940', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_716018', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_716096', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_716174', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_716252', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_716330', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_716408', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_716486', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_716564', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_716642', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_716720', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_716798', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_716876', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_716954', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_717032', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_717110', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_717188', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_717266', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_717344', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_717422', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_717500', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_717578', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_717656', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_717734', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_717812', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_717890', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_717968', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_718046', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_718124', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_718202', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_718280', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_718358', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_718436', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_718514', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_718592', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_718670', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_718748', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_718826', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_718904', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_718982', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_719060', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_719138', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_719216', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_719294', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_719372', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_719450', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_719528', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_719606', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_719684', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_719762', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_719840', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_719918', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_719996', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_720074', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_720152', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_720230', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_720308', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_720386', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_720464', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_720542', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_720620', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_720698', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_720776', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_720854', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}, {'UUID': 'DrugTargetsIndication121923_text_720932', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1041	Q16	What Small molecule therapies have been approved by the FDA to treat esophageal squamous cell carcinoma?	There are no drug Small molecule therapies approved to treat esophageal squamous cell carcinoma.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "esophageal squamous cell carcinoma" OR LOWER(mesh_heading) = "esophageal squamous cell carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1242	Q16	What Small molecule therapies have been approved by the FDA to treat lateral epicondylitis?	There are 3 Small molecule therapy drugs that are approved to treat lateral epicondylitis which are as follows: Prednisone, Triamcinolone Acetonide, and Dexamethasone.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "lateral epicondylitis" OR LOWER(mesh_heading) = "lateral epicondylitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_217676', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_217884', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_218092', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_218300', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_218508', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_218716', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_218924', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_219132', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_219340', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_219548', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_219756', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_219964', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_220172', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_220380', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_220588', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_220796', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_221885', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_221950', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_222015', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_222080', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_222145', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_222210', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_222275', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_222340', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_226374', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_226659', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_226944', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_227229', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_227514', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_227799', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_228084', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_228369', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_228654', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_228939', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_229224', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_229509', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_229794', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_230079', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_230364', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_230649', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_230934', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_231219', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_231504', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_231789', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_232074', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_232359', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.605	Q16	What Small molecule therapies have been approved by the FDA to treat Pure red cell aplasia?	There are no drug Small molecule therapies approved to treat Pure red cell aplasia.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "pure red cell aplasia" OR LOWER(mesh_heading) = "pure red cell aplasia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1178	Q16	What Small molecule therapies have been approved by the FDA to treat hypoxemia?	There are no drug Small molecule therapies approved to treat hypoxemia.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "hypoxemia" OR LOWER(mesh_heading) = "hypoxemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.245	Q16	What Protein therapies have been approved by the FDA to treat osteoarthritis?	There are no drug Protein therapies approved to treat osteoarthritis.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "osteoarthritis" OR LOWER(mesh_heading) = "osteoarthritis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.709	Q16	What Small molecule therapies have been approved by the FDA to treat acute myeloid leukemia?	There are 5 Small molecule therapy drugs that are approved to treat acute myeloid leukemia which are as follows: Midostaurin, Ivosidenib, Gilteritinib Fumarate, Glasdegib Maleate, and Enasidenib Mesylate.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "acute myeloid leukemia" OR LOWER(mesh_heading) = "acute myeloid leukemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_667279', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667290', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667301', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667312', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122025', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667323', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122025', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667334', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122025', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667345', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667356', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667367', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667378', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667389', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667400', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667411', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667422', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667433', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667444', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171132', 'approvedSymbol': 'PRKCE', 'approvedName': 'protein kinase C epsilon', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667455', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171132', 'approvedSymbol': 'PRKCE', 'approvedName': 'protein kinase C epsilon', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667466', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171132', 'approvedSymbol': 'PRKCE', 'approvedName': 'protein kinase C epsilon', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667477', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000166501', 'approvedSymbol': 'PRKCB', 'approvedName': 'protein kinase C beta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667488', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000166501', 'approvedSymbol': 'PRKCB', 'approvedName': 'protein kinase C beta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667499', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000166501', 'approvedSymbol': 'PRKCB', 'approvedName': 'protein kinase C beta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667510', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000115825', 'approvedSymbol': 'PRKD3', 'approvedName': 'protein kinase D3', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667521', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000115825', 'approvedSymbol': 'PRKD3', 'approvedName': 'protein kinase D3', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667532', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000115825', 'approvedSymbol': 'PRKD3', 'approvedName': 'protein kinase D3', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667543', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163558', 'approvedSymbol': 'PRKCI', 'approvedName': 'protein kinase C iota', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667554', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163558', 'approvedSymbol': 'PRKCI', 'approvedName': 'protein kinase C iota', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667565', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163558', 'approvedSymbol': 'PRKCI', 'approvedName': 'protein kinase C iota', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667576', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000154229', 'approvedSymbol': 'PRKCA', 'approvedName': 'protein kinase C alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667587', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000154229', 'approvedSymbol': 'PRKCA', 'approvedName': 'protein kinase C alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667598', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000154229', 'approvedSymbol': 'PRKCA', 'approvedName': 'protein kinase C alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667609', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126583', 'approvedSymbol': 'PRKCG', 'approvedName': 'protein kinase C gamma', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667620', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126583', 'approvedSymbol': 'PRKCG', 'approvedName': 'protein kinase C gamma', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667631', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126583', 'approvedSymbol': 'PRKCG', 'approvedName': 'protein kinase C gamma', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667642', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163932', 'approvedSymbol': 'PRKCD', 'approvedName': 'protein kinase C delta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667653', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163932', 'approvedSymbol': 'PRKCD', 'approvedName': 'protein kinase C delta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667664', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163932', 'approvedSymbol': 'PRKCD', 'approvedName': 'protein kinase C delta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667675', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000067606', 'approvedSymbol': 'PRKCZ', 'approvedName': 'protein kinase C zeta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667686', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000067606', 'approvedSymbol': 'PRKCZ', 'approvedName': 'protein kinase C zeta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667697', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000067606', 'approvedSymbol': 'PRKCZ', 'approvedName': 'protein kinase C zeta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667708', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000027075', 'approvedSymbol': 'PRKCH', 'approvedName': 'protein kinase C eta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667719', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000027075', 'approvedSymbol': 'PRKCH', 'approvedName': 'protein kinase C eta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667730', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000027075', 'approvedSymbol': 'PRKCH', 'approvedName': 'protein kinase C eta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667741', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000184304', 'approvedSymbol': 'PRKD1', 'approvedName': 'protein kinase D1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667752', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000184304', 'approvedSymbol': 'PRKD1', 'approvedName': 'protein kinase D1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667763', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000184304', 'approvedSymbol': 'PRKD1', 'approvedName': 'protein kinase D1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667774', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065675', 'approvedSymbol': 'PRKCQ', 'approvedName': 'protein kinase C theta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667785', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065675', 'approvedSymbol': 'PRKCQ', 'approvedName': 'protein kinase C theta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667796', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065675', 'approvedSymbol': 'PRKCQ', 'approvedName': 'protein kinase C theta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924559', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924568', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924577', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924586', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924595', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924604', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924613', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924622', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924631', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924640', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924649', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924658', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924667', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924676', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924685', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924694', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924703', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924712', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924721', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924730', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924739', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924748', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924757', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924766', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924775', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924784', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_924793', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000138413', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_933929', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_list': "['Xospata']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122025', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_933931', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_list': "['Xospata']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122025', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_933933', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_list': "['Xospata']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122025', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_933935', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_list': "['Xospata']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167601', 'approvedSymbol': 'AXL', 'approvedName': 'AXL receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_933937', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_list': "['Xospata']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167601', 'approvedSymbol': 'AXL', 'approvedName': 'AXL receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_933939', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_list': "['Xospata']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167601', 'approvedSymbol': 'AXL', 'approvedName': 'AXL receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1072612', 'drugName': 'Glasdegib Maleate', 'tradeNames_list': "['Daurismo']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000128602', 'approvedSymbol': 'SMO', 'approvedName': 'smoothened, frizzled class receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1072613', 'drugName': 'Glasdegib Maleate', 'tradeNames_list': "['Daurismo']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000128602', 'approvedSymbol': 'SMO', 'approvedName': 'smoothened, frizzled class receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1072614', 'drugName': 'Glasdegib Maleate', 'tradeNames_list': "['Daurismo']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000128602', 'approvedSymbol': 'SMO', 'approvedName': 'smoothened, frizzled class receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1072615', 'drugName': 'Glasdegib Maleate', 'tradeNames_list': "['Daurismo']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000128602', 'approvedSymbol': 'SMO', 'approvedName': 'smoothened, frizzled class receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1072616', 'drugName': 'Glasdegib Maleate', 'tradeNames_list': "['Daurismo']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000128602', 'approvedSymbol': 'SMO', 'approvedName': 'smoothened, frizzled class receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1072617', 'drugName': 'Glasdegib Maleate', 'tradeNames_list': "['Daurismo']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000128602', 'approvedSymbol': 'SMO', 'approvedName': 'smoothened, frizzled class receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1072618', 'drugName': 'Glasdegib Maleate', 'tradeNames_list': "['Daurismo']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000128602', 'approvedSymbol': 'SMO', 'approvedName': 'smoothened, frizzled class receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1072619', 'drugName': 'Glasdegib Maleate', 'tradeNames_list': "['Daurismo']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000128602', 'approvedSymbol': 'SMO', 'approvedName': 'smoothened, frizzled class receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192240', 'drugName': 'Enasidenib Mesylate', 'tradeNames_list': "['Idhifa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182054', 'approvedSymbol': 'IDH2', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192241', 'drugName': 'Enasidenib Mesylate', 'tradeNames_list': "['Idhifa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182054', 'approvedSymbol': 'IDH2', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192242', 'drugName': 'Enasidenib Mesylate', 'tradeNames_list': "['Idhifa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182054', 'approvedSymbol': 'IDH2', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192243', 'drugName': 'Enasidenib Mesylate', 'tradeNames_list': "['Idhifa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182054', 'approvedSymbol': 'IDH2', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192244', 'drugName': 'Enasidenib Mesylate', 'tradeNames_list': "['Idhifa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182054', 'approvedSymbol': 'IDH2', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192245', 'drugName': 'Enasidenib Mesylate', 'tradeNames_list': "['Idhifa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182054', 'approvedSymbol': 'IDH2', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192246', 'drugName': 'Enasidenib Mesylate', 'tradeNames_list': "['Idhifa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182054', 'approvedSymbol': 'IDH2', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192247', 'drugName': 'Enasidenib Mesylate', 'tradeNames_list': "['Idhifa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182054', 'approvedSymbol': 'IDH2', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192248', 'drugName': 'Enasidenib Mesylate', 'tradeNames_list': "['Idhifa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182054', 'approvedSymbol': 'IDH2', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192249', 'drugName': 'Enasidenib Mesylate', 'tradeNames_list': "['Idhifa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182054', 'approvedSymbol': 'IDH2', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192250', 'drugName': 'Enasidenib Mesylate', 'tradeNames_list': "['Idhifa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182054', 'approvedSymbol': 'IDH2', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1295	Q16	What Small molecule therapies have been approved by the FDA to treat mast-cell leukemia?	Midostaurin is the only Small molecule therapy approved by the FDA to treat mast-cell leukemia.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "mast-cell leukemia" OR LOWER(mesh_heading) = "mast-cell leukemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_667281', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667292', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667303', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667314', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122025', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667325', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122025', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667336', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122025', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667347', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667358', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667369', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667380', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667391', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667402', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667413', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667424', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667435', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667446', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171132', 'approvedSymbol': 'PRKCE', 'approvedName': 'protein kinase C epsilon', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667457', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171132', 'approvedSymbol': 'PRKCE', 'approvedName': 'protein kinase C epsilon', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667468', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171132', 'approvedSymbol': 'PRKCE', 'approvedName': 'protein kinase C epsilon', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667479', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000166501', 'approvedSymbol': 'PRKCB', 'approvedName': 'protein kinase C beta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667490', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000166501', 'approvedSymbol': 'PRKCB', 'approvedName': 'protein kinase C beta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667501', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000166501', 'approvedSymbol': 'PRKCB', 'approvedName': 'protein kinase C beta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667512', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000115825', 'approvedSymbol': 'PRKD3', 'approvedName': 'protein kinase D3', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667523', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000115825', 'approvedSymbol': 'PRKD3', 'approvedName': 'protein kinase D3', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667534', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000115825', 'approvedSymbol': 'PRKD3', 'approvedName': 'protein kinase D3', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667545', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163558', 'approvedSymbol': 'PRKCI', 'approvedName': 'protein kinase C iota', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667556', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163558', 'approvedSymbol': 'PRKCI', 'approvedName': 'protein kinase C iota', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667567', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163558', 'approvedSymbol': 'PRKCI', 'approvedName': 'protein kinase C iota', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667578', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000154229', 'approvedSymbol': 'PRKCA', 'approvedName': 'protein kinase C alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667589', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000154229', 'approvedSymbol': 'PRKCA', 'approvedName': 'protein kinase C alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667600', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000154229', 'approvedSymbol': 'PRKCA', 'approvedName': 'protein kinase C alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667611', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126583', 'approvedSymbol': 'PRKCG', 'approvedName': 'protein kinase C gamma', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667622', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126583', 'approvedSymbol': 'PRKCG', 'approvedName': 'protein kinase C gamma', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667633', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126583', 'approvedSymbol': 'PRKCG', 'approvedName': 'protein kinase C gamma', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667644', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163932', 'approvedSymbol': 'PRKCD', 'approvedName': 'protein kinase C delta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667655', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163932', 'approvedSymbol': 'PRKCD', 'approvedName': 'protein kinase C delta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667666', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163932', 'approvedSymbol': 'PRKCD', 'approvedName': 'protein kinase C delta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667677', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000067606', 'approvedSymbol': 'PRKCZ', 'approvedName': 'protein kinase C zeta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667688', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000067606', 'approvedSymbol': 'PRKCZ', 'approvedName': 'protein kinase C zeta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667699', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000067606', 'approvedSymbol': 'PRKCZ', 'approvedName': 'protein kinase C zeta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667710', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000027075', 'approvedSymbol': 'PRKCH', 'approvedName': 'protein kinase C eta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667721', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000027075', 'approvedSymbol': 'PRKCH', 'approvedName': 'protein kinase C eta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667732', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000027075', 'approvedSymbol': 'PRKCH', 'approvedName': 'protein kinase C eta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667743', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000184304', 'approvedSymbol': 'PRKD1', 'approvedName': 'protein kinase D1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667754', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000184304', 'approvedSymbol': 'PRKD1', 'approvedName': 'protein kinase D1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667765', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000184304', 'approvedSymbol': 'PRKD1', 'approvedName': 'protein kinase D1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667776', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065675', 'approvedSymbol': 'PRKCQ', 'approvedName': 'protein kinase C theta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667787', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065675', 'approvedSymbol': 'PRKCQ', 'approvedName': 'protein kinase C theta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_667798', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065675', 'approvedSymbol': 'PRKCQ', 'approvedName': 'protein kinase C theta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Mast-Cell', 'efo_term': 'mast-cell leukemia'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.314	Q16	What Protein therapies have been approved by the FDA to treat urticaria?	There are no drug Protein therapies approved to treat urticaria.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "urticaria" OR LOWER(mesh_heading) = "urticaria") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.439	Q16	What Small molecule therapies have been approved by the FDA to treat Familial adenomatous polyposis?	Celecoxib is the only Small molecule therapy approved by the FDA to treat Familial adenomatous polyposis.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "familial adenomatous polyposis" OR LOWER(mesh_heading) = "familial adenomatous polyposis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_832947', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenomatous Polyposis Coli', 'efo_term': 'Familial adenomatous polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_833058', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenomatous Polyposis Coli', 'efo_term': 'Familial adenomatous polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_833169', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenomatous Polyposis Coli', 'efo_term': 'Familial adenomatous polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_833280', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenomatous Polyposis Coli', 'efo_term': 'Familial adenomatous polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_833391', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenomatous Polyposis Coli', 'efo_term': 'Familial adenomatous polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_833502', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenomatous Polyposis Coli', 'efo_term': 'Familial adenomatous polyposis'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1668	Q16	What Small molecule therapies have been approved by the FDA to treat substance withdrawal syndrome?	There are no drug Small molecule therapies approved to treat substance withdrawal syndrome.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "substance withdrawal syndrome" OR LOWER(mesh_heading) = "substance withdrawal syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1179	Q16	What Small molecule therapies have been approved by the FDA to treat hypoxia?	There are no drug Small molecule therapies approved to treat hypoxia.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "hypoxia" OR LOWER(mesh_heading) = "hypoxia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.310	Q16	What Protein therapies have been approved by the FDA to treat tropical spastic paraparesis?	There are no drug Protein therapies approved to treat tropical spastic paraparesis.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "tropical spastic paraparesis" OR LOWER(mesh_heading) = "tropical spastic paraparesis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.434	Q16	What Small molecule therapies have been approved by the FDA to treat Extramammary Paget Disease?	There are no drug Small molecule therapies approved to treat Extramammary Paget Disease.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "extramammary paget disease" OR LOWER(mesh_heading) = "extramammary paget disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.373	Q16	What Small molecule therapies have been approved by the FDA to treat Burkitts lymphoma?	There are no drug Small molecule therapies approved to treat Burkitts lymphoma.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "burkitts lymphoma" OR LOWER(mesh_heading) = "burkitts lymphoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.570	Q16	What Small molecule therapies have been approved by the FDA to treat Non-ST Elevation Myocardial Infarction?	There are no drug Small molecule therapies approved to treat Non-ST Elevation Myocardial Infarction.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "non-st elevation myocardial infarction" OR LOWER(mesh_heading) = "non-st elevation myocardial infarction") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1018	Q16	What Small molecule therapies have been approved by the FDA to treat endometrial cancer?	There are no drug Small molecule therapies approved to treat endometrial cancer.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "endometrial cancer" OR LOWER(mesh_heading) = "endometrial cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.182	Q16	What Protein therapies have been approved by the FDA to treat infertility?	There are no drug Protein therapies approved to treat infertility.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "infertility" OR LOWER(mesh_heading) = "infertility") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1379	Q16	What Small molecule therapies have been approved by the FDA to treat neuromyelitis optica?	There are no drug Small molecule therapies approved to treat neuromyelitis optica.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "neuromyelitis optica" OR LOWER(mesh_heading) = "neuromyelitis optica") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.699	Q16	What Small molecule therapies have been approved by the FDA to treat acute erythroblastic leukemia?	There are no drug Small molecule therapies approved to treat acute erythroblastic leukemia.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "acute erythroblastic leukemia" OR LOWER(mesh_heading) = "acute erythroblastic leukemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1083	Q16	What Small molecule therapies have been approved by the FDA to treat fragile X syndrome?	There are no drug Small molecule therapies approved to treat fragile X syndrome.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "fragile x syndrome" OR LOWER(mesh_heading) = "fragile x syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1748	Q16	What Small molecule therapies have been approved by the FDA to treat venous thromboembolism?	Betrixaban is the only Small molecule therapy approved by the FDA to treat venous thromboembolism.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "venous thromboembolism" OR LOWER(mesh_heading) = "venous thromboembolism") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_710779', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism'}, {'UUID': 'DrugTargetsIndication121923_text_710787', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism'}, {'UUID': 'DrugTargetsIndication121923_text_710795', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism'}, {'UUID': 'DrugTargetsIndication121923_text_710803', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism'}, {'UUID': 'DrugTargetsIndication121923_text_710811', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism'}, {'UUID': 'DrugTargetsIndication121923_text_710819', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism'}, {'UUID': 'DrugTargetsIndication121923_text_710827', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism'}, {'UUID': 'DrugTargetsIndication121923_text_710835', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism'}, {'UUID': 'DrugTargetsIndication121923_text_710843', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism'}, {'UUID': 'DrugTargetsIndication121923_text_710851', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism'}, {'UUID': 'DrugTargetsIndication121923_text_710859', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism'}, {'UUID': 'DrugTargetsIndication121923_text_710867', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1618	Q16	What Small molecule therapies have been approved by the FDA to treat severe aplastic anemia?	Eltrombopag Olamine is the only Small molecule therapy approved by the FDA to treat severe aplastic anemia.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "severe aplastic anemia" OR LOWER(mesh_heading) = "severe aplastic anemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_1055949', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1055954', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1055959', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1055964', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1055969', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1055974', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1055979', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1055984', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1055989', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1055994', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1055999', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056004', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056009', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056014', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056019', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056024', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056029', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056034', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056039', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056044', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056049', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056054', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056059', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056064', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056069', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056074', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056079', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056084', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056089', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056094', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056099', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056104', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056109', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056114', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056119', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056124', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056129', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056134', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056139', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056144', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056149', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056154', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056159', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056164', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056169', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056174', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056179', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056184', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056189', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056194', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056199', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056204', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056209', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056214', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056219', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056224', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056229', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056234', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056239', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056244', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056249', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056254', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056259', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056264', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056269', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056274', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056279', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056284', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056289', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056294', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056299', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056304', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056309', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056314', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056319', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056324', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056329', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056334', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056339', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056344', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056349', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056354', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056359', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056364', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056369', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056374', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056379', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056384', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056389', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056394', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056399', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056404', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056409', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056414', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056419', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056424', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056429', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056434', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056439', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1056444', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'severe aplastic anemia'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.298	Q16	What Protein therapies have been approved by the FDA to treat smoking cessation?	There are no drug Protein therapies approved to treat smoking cessation.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "smoking cessation" OR LOWER(mesh_heading) = "smoking cessation") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.718	Q16	What Small molecule therapies have been approved by the FDA to treat adrenal cortex carcinoma?	There are no drug Small molecule therapies approved to treat adrenal cortex carcinoma.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "adrenal cortex carcinoma" OR LOWER(mesh_heading) = "adrenal cortex carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.465	Q16	What Small molecule therapies have been approved by the FDA to treat HER2 Positive Breast Carcinoma?	Tucatinib is the only Small molecule therapy approved by the FDA to treat HER2 Positive Breast Carcinoma.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "her2 positive breast carcinoma" OR LOWER(mesh_heading) = "her2 positive breast carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_924453', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'HER2 Positive Breast Carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924467', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'HER2 Positive Breast Carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924481', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'HER2 Positive Breast Carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924495', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'HER2 Positive Breast Carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924509', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'HER2 Positive Breast Carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924523', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'HER2 Positive Breast Carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924537', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'HER2 Positive Breast Carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924551', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'HER2 Positive Breast Carcinoma'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1383	Q16	What Small molecule therapies have been approved by the FDA to treat neutropenia?	There are no drug Small molecule therapies approved to treat neutropenia.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "neutropenia" OR LOWER(mesh_heading) = "neutropenia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1121	Q16	What Small molecule therapies have been approved by the FDA to treat hand dermatosis?	There are no drug Small molecule therapies approved to treat hand dermatosis.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "hand dermatosis" OR LOWER(mesh_heading) = "hand dermatosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.380	Q16	What Small molecule therapies have been approved by the FDA to treat Cerebral arteriovenous malformation?	There are no drug Small molecule therapies approved to treat Cerebral arteriovenous malformation.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "cerebral arteriovenous malformation" OR LOWER(mesh_heading) = "cerebral arteriovenous malformation") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1087	Q16	What Small molecule therapies have been approved by the FDA to treat fungal infectious disease?	There are 2 Small molecule therapy drugs that are approved to treat fungal infectious disease which are as follows: Triamcinolone Acetonide and Methotrexate.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "fungal infectious disease" OR LOWER(mesh_heading) = "fungal infectious disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_221886', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycoses', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_221951', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycoses', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_222016', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycoses', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_222081', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycoses', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_222146', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycoses', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_222211', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycoses', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_222276', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycoses', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_222341', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycoses', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1056795', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1056956', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1057117', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1057278', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1057439', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1057600', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1057761', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1057922', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1058083', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1058244', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1058405', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1058566', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1058727', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1058888', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1059049', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1059210', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1059371', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1059532', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1059693', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1059854', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1060015', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1060176', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1060337', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1060498', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1060659', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1060820', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1060981', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1061142', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1061303', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1061464', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1061625', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1061786', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1061947', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1062108', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1062269', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1062430', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1062591', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1062752', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1062913', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1063074', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1063235', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1063396', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1063557', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1063718', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1063879', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1064040', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1064201', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1064362', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1064523', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1064684', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1064845', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1065006', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1065167', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1065328', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1065489', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1065650', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1065811', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1065972', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1066133', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1066294', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1066455', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1066616', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1066777', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1066938', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1067099', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1067260', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1067421', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1067582', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1067743', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1067904', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1068065', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1068226', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1068387', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1068548', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1068709', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1068870', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1069031', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1069192', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1069353', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1069514', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1069675', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1069836', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1069997', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1070158', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1070319', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1070480', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1070641', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1070802', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1070963', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1071124', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1071285', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1071446', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.987	Q16	What Small molecule therapies have been approved by the FDA to treat diabetic foot?	There are no drug Small molecule therapies approved to treat diabetic foot.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "diabetic foot" OR LOWER(mesh_heading) = "diabetic foot") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.127	Q16	What Protein therapies have been approved by the FDA to treat chronic lymphocytic leukemia?	There are no drug Protein therapies approved to treat chronic lymphocytic leukemia.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "chronic lymphocytic leukemia" OR LOWER(mesh_heading) = "chronic lymphocytic leukemia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.984	Q16	What Small molecule therapies have been approved by the FDA to treat developmental and epileptic encephalopathy?	There are no drug Small molecule therapies approved to treat developmental and epileptic encephalopathy.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "developmental and epileptic encephalopathy" OR LOWER(mesh_heading) = "developmental and epileptic encephalopathy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1405	Q16	What Small molecule therapies have been approved by the FDA to treat oral lichen planus?	There are no drug Small molecule therapies approved to treat oral lichen planus.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "oral lichen planus" OR LOWER(mesh_heading) = "oral lichen planus") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.358	Q16	What Small molecule therapies have been approved by the FDA to treat Barrett's esophagus?	There are no drug Small molecule therapies approved to treat Barrett's esophagus.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "barrett's esophagus" OR LOWER(mesh_heading) = "barrett's esophagus") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1427	Q16	What Small molecule therapies have been approved by the FDA to treat otitis media with effusion?	There are no drug Small molecule therapies approved to treat otitis media with effusion.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "otitis media with effusion" OR LOWER(mesh_heading) = "otitis media with effusion") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1430	Q16	What Small molecule therapies have been approved by the FDA to treat ovarian hyperstimulation syndrome?	There are no drug Small molecule therapies approved to treat ovarian hyperstimulation syndrome.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "ovarian hyperstimulation syndrome" OR LOWER(mesh_heading) = "ovarian hyperstimulation syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1715	Q16	What Small molecule therapies have been approved by the FDA to treat type III hypersensitivity reaction disease?	There are 4 Small molecule therapy drugs that are approved to treat type III hypersensitivity reaction disease which are as follows: Prednisone, Triamcinolone Acetonide, Dexamethasone, and Epinephrine.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "type iii hypersensitivity reaction disease" OR LOWER(mesh_heading) = "type iii hypersensitivity reaction disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[{'UUID': 'DrugTargetsIndication121923_text_217674', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_217882', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_218090', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_218298', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_218506', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_218714', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_218922', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_219130', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_219338', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_219546', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_219754', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_219962', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_220170', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_220378', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_220586', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_220794', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_221882', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_221947', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_222012', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_222077', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_222142', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_222207', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_222272', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_222337', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_226371', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_226656', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_226941', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_227226', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_227511', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_227796', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_228081', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_228366', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_228651', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_228936', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_229221', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_229506', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_229791', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_230076', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_230361', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_230646', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_230931', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_231216', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_231501', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_231786', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_232071', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_232356', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_360834', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_360887', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_360940', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_360993', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_361046', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_361099', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_361152', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_361205', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_361258', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_361311', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_361364', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_361417', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_361470', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_361523', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_361576', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_361629', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_361682', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_361735', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_361788', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_361841', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_361894', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_361947', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_362000', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_362053', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_362106', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_362159', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_362212', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_362265', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_362318', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_362371', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_362424', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_362477', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_362530', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_362583', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_362636', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_362689', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_362742', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_362795', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_362848', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_362901', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_362954', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_363007', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_363060', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_363113', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_363166', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_363219', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_363272', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_363325', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_363378', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_363431', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_363484', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_363537', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_363590', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}, {'UUID': 'DrugTargetsIndication121923_text_363643', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease'}]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.210	Q16	What Protein therapies have been approved by the FDA to treat male breast carcinoma?	There are no drug Protein therapies approved to treat male breast carcinoma.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "male breast carcinoma" OR LOWER(mesh_heading) = "male breast carcinoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1648	Q16	What Small molecule therapies have been approved by the FDA to treat spinocerebellar ataxia type 2?	There are no drug Small molecule therapies approved to treat spinocerebellar ataxia type 2.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "spinocerebellar ataxia type 2" OR LOWER(mesh_heading) = "spinocerebellar ataxia type 2") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.141	Q16	What Protein therapies have been approved by the FDA to treat dense deposit disease?	There are no drug Protein therapies approved to treat dense deposit disease.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "dense deposit disease" OR LOWER(mesh_heading) = "dense deposit disease") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1738	Q16	What Small molecule therapies have been approved by the FDA to treat uterine neoplasm?	There are no drug Small molecule therapies approved to treat uterine neoplasm.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "uterine neoplasm" OR LOWER(mesh_heading) = "uterine neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1173	Q16	What Small molecule therapies have been approved by the FDA to treat hypospadias?	There are no drug Small molecule therapies approved to treat hypospadias.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "hypospadias" OR LOWER(mesh_heading) = "hypospadias") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status
Q16.1602	Q16	What Small molecule therapies have been approved by the FDA to treat schizotypal personality disorder?	There are no drug Small molecule therapies approved to treat schizotypal personality disorder.	SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses` WHERE (LOWER(efo_term) = "schizotypal personality disorder" OR LOWER(mesh_heading) = "schizotypal personality disorder") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0 LIMIT 100	[]	refined	Distinct, Multi-Filter, Similarity Search	Approval Status

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.